AstraZeneca PLC [NASDAQ: AZN] slipped around -0.36 points on Wednesday, while shares priced at $66.12 at the close of the session, down -0.54%. The company report on May 27, 2022 that First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Anifrolumab is a first-in-class type I interferon receptor antibody.
The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis (LN).
AstraZeneca PLC stock is now 13.51% up from its year-to-date (YTD) trading value. AZN Stock saw the intraday high of $66.69 and lowest of $65.495 per share. The company’s 52-week high price is 71.70, which means current price is +19.14% above from all time high which was touched on 04/08/22.
Compared to the average trading volume of 7.23M shares, AZN reached a trading volume of 5265036 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about AstraZeneca PLC [AZN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $71.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
DZ Bank have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Hold, with their previous recommendation back on February 11, 2022. The new note on the price target was released on December 07, 2021, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 1.38, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 4.85. The Price to Book ratio for the last quarter was 5.63, with the Price to Cash per share for the same quarter was set at 1.91. Price to Free Cash Flow for AZN in the course of the last twelve months was 111.09 with Quick ratio for the last quarter at 0.70.
How has AZN stock performed recently?
AstraZeneca PLC [AZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.80. With this latest performance, AZN shares dropped by -0.47% in over the last four-week period, additionally plugging by 20.59% over the last 6 months – not to mention a rise of 17.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 52.00, with the RSI for the last a single of trading hit 52.39, and the three-weeks RSI is set at 52.06 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 66.31, while it was recorded at 66.70 for the last single week of trading, and 60.70 for the last 200 days.
AstraZeneca PLC [AZN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +7.57 and a Gross Margin at +60.90. AstraZeneca PLC’s Net Margin is presently recorded at +0.30.
Return on Total Capital for AZN is now 5.33, given the latest momentum, and Return on Invested Capital for the company is 0.22. Return on Equity for this stock inclined to 0.40, with Return on Assets sitting at 0.13. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 78.39. Additionally, AZN Total Debt to Total Capital is recorded at 43.94, with Total Debt to Total Assets ending up at 29.21. Long-Term Debt to Equity for the company is recorded at 73.57, with the Long-Term Debt to Total Capital now at 41.24.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $980 per employee. Receivables Turnover for the company is 5.18 with a Total Asset Turnover recorded at a value of 0.43.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.
Earnings analysis for AstraZeneca PLC [AZN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 15.40%.
Insider trade positions for AstraZeneca PLC [AZN]
There are presently around $34,493 million, or 17.70% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 94,229,869, which is approximately 4.885% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 46,691,035 shares of the stock with an approximate value of $3.1 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $3.08 billion in AZN stock with ownership of nearly -0.798% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 455 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 50,437,977 shares. Additionally, 393 investors decreased positions by around 36,980,976 shares, while 213 investors held positions by with 431,421,810 shares. The mentioned changes placed institutional holdings at 518,840,763 shares, according to the latest SEC report filing. AZN stock had 112 new institutional investments in for a total of 4,943,089 shares, while 88 institutional investors sold positions of 5,571,313 shares during the same period.